# Organovo Holdings Inc. (ONVO)

Source: https://www.quantisnow.com/company/ONVO
Generated: 2026-11-18T20:15:37.881Z

- Ticker: ONVO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- Website: organovo.com

## About

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

## Latest ONVO news and filings

- 2025-04-24 12:30 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-amendments-to-articles-5999824)
- 2025-04-24 12:05 UTC [VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market](https://www.quantisnow.com/insight/vivosim-announces-emergence-from-stealth-mode-to-provide-technologies-for-5999747)
- 2025-04-23 12:06 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-regulation-fd-disclosure-5997411)
- 2025-04-23 12:05 UTC [VivoSim to Carry Forward Organovo 3D Bioprinting](https://www.quantisnow.com/insight/vivosim-to-carry-forward-organovo-3d-bioprinting-5997408)
- 2025-04-11 13:16 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-organovo-holdings-inc-5985268)
- 2025-04-02 12:06 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-results-of-operations-5971213)
- 2025-04-02 12:05 UTC [Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements](https://www.quantisnow.com/insight/organovo-provides-update-on-cash-and-nasdaq-continued-listing-requirements-5971201)
- 2025-03-27 12:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-regulation-fd-disclosure-5962308)
- 2025-03-27 12:05 UTC [Organovo Provides Business Update](https://www.quantisnow.com/insight/organovo-provides-business-update-5962307)
- 2025-03-26 12:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-completion-of-acquisition-5960484)
- 2025-03-25 15:25 UTC [Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company](https://www.quantisnow.com/insight/organovo-announces-close-of-the-sale-of-fxr-program-to-5959066)
- 2025-03-21 12:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-material-modification-to-5955410)
- 2025-03-19 12:06 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-regulation-fd-disclosure-5951635)
- 2025-03-19 12:05 UTC [Organovo Announces Reverse Stock Split](https://www.quantisnow.com/insight/organovo-announces-reverse-stock-split-5951631)
- 2025-03-11 11:00 UTC [Leadership Update] [Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors](https://www.quantisnow.com/insight/matinas-biopharma-appoints-seasoned-biotech-leaders-to-board-of-directors-5937169)
- 2025-03-06 13:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-other-events-financial-5930197)
- 2025-03-06 13:05 UTC [Organovo Announces the Issuance of Additional Shares  in Conjunction with Warrant Exercises](https://www.quantisnow.com/insight/organovo-announces-the-issuance-of-additional-shares-in-conjunction-with-5930195)
- 2025-02-26 11:06 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-organovo-holdings-inc-5909991)
- 2025-02-25 13:06 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-entry-into-a-5907240)
- 2025-02-25 13:05 UTC [Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company](https://www.quantisnow.com/insight/organovos-fxr-program-including-fxr314-to-be-acquired-by-eli-5907236)
- 2025-02-19 14:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-organovo-holdings-inc-5895981)
- 2025-02-14 21:05 UTC [SEC Form NT 10-Q filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-organovo-holdings-inc-5890416)
- 2025-01-17 22:30 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-notice-of-delisting-5850448)
- 2025-01-08 21:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Staskey Norm](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-staskey-norm-5839601)
- 2025-01-06 13:05 UTC [Leadership Update] [Organovo Announces Appointment of Norman Staskey as Chief Financial Officer](https://www.quantisnow.com/insight/organovo-announces-appointment-of-norman-staskey-as-chief-financial-officer-5833822)
- 2024-12-31 13:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-leadership-update-financial-5827515)
- 2024-11-22 13:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-leadership-update-submission-5787825)
- 2024-11-20 13:05 UTC [Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting](https://www.quantisnow.com/insight/organovo-presents-clinical-data-of-fxr314-in-phase-2-mash-5784380)
- 2024-11-14 20:34 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-organovo-holdings-inc-5775144)
- 2024-11-08 21:04 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-organovo-holdings-inc-5762394)
- 2024-10-25 21:00 UTC [SEC Form S-1] [SEC Form S-1 filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-organovo-holdings-inc-5738917)
- 2024-09-18 20:05 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-organovo-holdings-inc-5698102)
- 2024-08-09 20:05 UTC [SEC Form 8-K] [Organovo Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/organovo-holdings-inc-filed-sec-form-8-k-leadership-update-financial-5652729)
- 2024-08-09 20:01 UTC [SEC Form 4] [Director Gobel David was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)](https://www.quantisnow.com/insight/director-gobel-david-was-granted-19607-shares-increasing-direct-ownership-5652662)
- 2024-08-09 20:01 UTC [SEC Form 4] [Director Milhous Alison Tjosvold was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)](https://www.quantisnow.com/insight/director-milhous-alison-tjosvold-was-granted-19607-shares-increasing-direct-5652657)
- 2024-08-09 20:01 UTC [SEC Form 4] [Director Cohen Douglas Jay was granted 19,607 shares, increasing direct ownership by 40% to 68,821 units (SEC Form 4)](https://www.quantisnow.com/insight/director-cohen-douglas-jay-was-granted-19607-shares-increasing-direct-5652652)
- 2024-08-09 20:01 UTC [SEC Form 4] [Director Stern Adam K was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)](https://www.quantisnow.com/insight/director-stern-adam-k-was-granted-19607-shares-increasing-direct-5652651)
- 2024-08-09 20:01 UTC [SEC Form 4] [Director Joshi Vaidehi was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)](https://www.quantisnow.com/insight/director-joshi-vaidehi-was-granted-19607-shares-increasing-direct-ownership-5652648)
- 2024-08-07 20:01 UTC [SEC Form 4] [EXECUTIVE CHAIRMAN Murphy Keith was granted 19,607 shares, increasing direct ownership by 17% to 132,641 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-chairman-murphy-keith-was-granted-19607-shares-increasing-direct-5647103)
- 2024-08-05 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Organovo Holdings Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-organovo-holdings-inc-5642164)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ONVO
- Earnings history: https://www.quantisnow.com/earnings/ONVO
- Dividend history: https://www.quantisnow.com/dividends/ONVO
- Insider transactions: https://www.quantisnow.com/insiders/ONVO
- Options chain: https://www.quantisnow.com/options/ONVO
- SEC 8-K filings only: https://www.quantisnow.com/company/ONVO/8-k
- RSS and alerts for ONVO: https://www.quantisnow.com/docs/rss-feeds.md
